This foundational study demonstrates that thromboxane A2 is formed in human platelets and is responsible for inducing irreversible platelet aggregation and granule release.
Answers are grounded in this paper and cite their sources.
Thromboxane A2 induces irreversible platelet aggregation; leaves open its in vivo role and therapeutic targeting in thrombosis.
Incubation of arachidonic acid and prostaglandin G2 with a suspension of human platelets led to formation of an unstable (t1/2, 41+/-7 s) compound, thromboxane A2. Thromboxane A2 induced irreversible aggregation of washed platelets and of platelets in platelet-rich plasma and caused release of serotonin and ADP from platelets in platelet-rich plasma.
No takes yet. Share an insight, caveat, or question.
Svensson et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: